🇺🇸 FDA
Patent

US 11229700

Trispecific molecule combining specific tumor targeting and local immune checkpoint inhibition

granted A61KA61K39/39541A61K39/3955

Quick answer

US patent 11229700 (Trispecific molecule combining specific tumor targeting and local immune checkpoint inhibition) held by Ludwig-Maximilians-Universitat Munchen expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ludwig-Maximilians-Universitat Munchen
Grant date
Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K39/39541, A61K39/3955, A61K39/39558, A61K39/39566